India, March 20 -- Sanofi (SNY), a French pharmaceutical and healthcare company, announced on Thursday that it has entered into a definitive agreement to acquire Dren Bio, Inc.'s DR-0201, a targeted bispecific myeloid cell engager. The consideration involves an upfront of $600 million and a milestone payment of $1.3 billion, to be paid using the company's cash resources.
Sanofi believes this deal could lead to the company becoming a leading immunology company.
The transaction is expected to close in the second quarter of 2025.
After the deal is complete, Dren Bio will continue working on its own to develop antibody therapeutics that target and eliminate harmful cells and disease-causing agents.
googletag.cmd.push(function() { googletag....